Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunohistochemical analysis of paraffin-embedded human lung adenocarcinoma (A), esophageal squamous cell carcinoma (B), hepatic cell carcinoma (C), thyroid tumor (D), breast adenofibroma (E), breast infiltrating ductal carcinoma (F), normal cerebrum tissue (G), normal colon tissue (H), normal esophageal tissue (I) using P16 monoclonal antibody (Product # MA5-17093) followed with DAB staining.
|Tested species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Purified recombinant fragment of P16 expressed in E. Coli.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (IHC)||1:200 - 1:1000|
|Western Blot (WB)||1:500 - 1:2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-17093 targets P16 in IHC and WB applications and shows reactivity with Human samples.
The MA5-17093 immunogen is purified recombinant fragment of P16 expressed in E. Coli.
p16 (cyclin-dependent kinase inhibitor 2A, INK4a) is a tumor suppressor protein. It is a specific inhibitor of Cdk 4 / Cdk 6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16 INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16 INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16 INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
alternative reading frame; CDK4 inhibitor p16-INK4; cell cycle negative regulator beta; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); multiple tumor suppressor 1
ARF; CDK4I; CDKN2; CDKN2A; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4; P16INK4A; P19; P19ARF; TP16